Steward Partners Investment Advisory LLC Boosts Stake in Merck & Co., Inc. (NYSE:MRK)

Steward Partners Investment Advisory LLC increased its stake in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 1.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 367,518 shares of the company’s stock after purchasing an additional 3,826 shares during the period. Steward Partners Investment Advisory LLC’s holdings in Merck & Co., Inc. were worth $40,067,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MRK. WealthPlan Investment Management LLC boosted its position in Merck & Co., Inc. by 3,477.6% in the 3rd quarter. WealthPlan Investment Management LLC now owns 10,232 shares of the company’s stock valued at $1,053,000 after buying an additional 9,946 shares during the period. Wealthspire Advisors LLC raised its holdings in shares of Merck & Co., Inc. by 37.0% in the 3rd quarter. Wealthspire Advisors LLC now owns 57,526 shares of the company’s stock valued at $5,922,000 after purchasing an additional 15,529 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its holdings in shares of Merck & Co., Inc. by 8.0% in the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,473,631 shares of the company’s stock valued at $254,660,000 after purchasing an additional 183,345 shares in the last quarter. Cornerstone Wealth Management LLC raised its holdings in shares of Merck & Co., Inc. by 7.0% in the 3rd quarter. Cornerstone Wealth Management LLC now owns 20,992 shares of the company’s stock valued at $2,161,000 after purchasing an additional 1,377 shares in the last quarter. Finally, Great Valley Advisor Group Inc. raised its holdings in shares of Merck & Co., Inc. by 10.8% in the 3rd quarter. Great Valley Advisor Group Inc. now owns 93,069 shares of the company’s stock valued at $9,581,000 after purchasing an additional 9,052 shares in the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Price Performance

Shares of Merck & Co., Inc. stock traded down $0.39 during trading on Wednesday, reaching $125.70. The company’s stock had a trading volume of 1,554,558 shares, compared to its average volume of 7,934,689. The business has a 50 day moving average price of $128.39 and a 200-day moving average price of $120.15. Merck & Co., Inc. has a 12-month low of $99.14 and a 12-month high of $133.10. The company has a market capitalization of $318.37 billion, a P/E ratio of 140.22, a price-to-earnings-growth ratio of 1.66 and a beta of 0.39. The company has a quick ratio of 0.99, a current ratio of 1.25 and a debt-to-equity ratio of 0.77.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last released its earnings results on Thursday, April 25th. The company reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.94 by $0.13. Merck & Co., Inc. had a return on equity of 14.05% and a net margin of 3.76%. The company had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.21 billion. During the same quarter last year, the company earned $1.40 earnings per share. Merck & Co., Inc.’s quarterly revenue was up 8.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Merck & Co., Inc. will post 8.69 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on MRK. TheStreet lowered shares of Merck & Co., Inc. from a “b+” rating to a “c+” rating in a report on Monday, March 4th. StockNews.com upgraded shares of Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a report on Friday, February 2nd. Berenberg Bank raised their price objective on shares of Merck & Co., Inc. from $140.00 to $143.00 and gave the company a “buy” rating in a report on Monday, April 8th. Wells Fargo & Company lifted their price target on shares of Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 27th. Finally, UBS Group lifted their price target on shares of Merck & Co., Inc. from $135.00 to $148.00 and gave the stock a “buy” rating in a research note on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $131.33.

Read Our Latest Stock Report on MRK

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Further Reading

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.